57 reports of this reaction
1.3% of all DIHYDROERGOTAMINE MESYLATE reports
#13 most reported adverse reaction
TREATMENT FAILURE is the #13 most commonly reported adverse reaction for DIHYDROERGOTAMINE MESYLATE, manufactured by Impel Pharmaceuticals LLC. There are 57 FDA adverse event reports linking DIHYDROERGOTAMINE MESYLATE to TREATMENT FAILURE. This represents approximately 1.3% of all 4,245 adverse event reports for this drug.
Patients taking DIHYDROERGOTAMINE MESYLATE who experience treatment failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TREATMENT FAILURE is a less commonly reported adverse event for DIHYDROERGOTAMINE MESYLATE, but still significant enough to appear in the safety profile.
In addition to treatment failure, the following adverse reactions have been reported for DIHYDROERGOTAMINE MESYLATE:
The following drugs have also been linked to treatment failure in FDA adverse event reports:
TREATMENT FAILURE has been reported as an adverse event in 57 FDA reports for DIHYDROERGOTAMINE MESYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TREATMENT FAILURE accounts for approximately 1.3% of all adverse event reports for DIHYDROERGOTAMINE MESYLATE, making it a notable side effect.
If you experience treatment failure while taking DIHYDROERGOTAMINE MESYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.